Numinus To Acquire Novamind For $20.74M In Stock
Numinus Wellness Inc. (TSX:NUMI)(OTCQX:NUMIF) and Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) have entered into a definitive arrangement agreement pursuant to which…
EXCLUSIVE: Bienstar Wellness Enters Brazilian Psychedelic Market, Will Acquire Ibogaine Co.
Bienstar Wellness Corp., an integrative mental health company specializing in psychedelic medicine with core operations in Latin America, has entered into a binding letter of intent to acquire 100% of BRC Saude Mental E Terapias Assistidas Ltda., a Brazilian psychedelic institution specialized in ibogaine treatment for substance ab
Novamind Stock Slightly Up On Grants Restricted Share Units
Novamind Inc. (OTCQB:NVMDF)(CSE:NM)(FSE:HN2) a mental health company specialized in psychedelic medicine, has granted an aggregate of 325,000 restricted…
Novamind To Conduct Phase II Psilocybin Trial For Major Depressive Disorder
Novamind Inc. (OTCQB:NVMDF) (CSE:NM)(FSE:HN2) will conduct a phase II clinical trial investigating psilocybin for major depressive disorder sponsored…
Benzinga Expands Footprint into the Psychedelic Industry with the Launch of the Benzinga Psychedelic Advisory Council
DETROIT, March 4, 2022 /PRNewswire/ -- The Benzinga Psychedelics Advisory Council is a collective of the leading minds and voices in the psychedelics space, composed of key thought leaders sharing insights into industry developments, sector trends and breaking news.
Novamind Posts Record High Revenue Of CA$2.45M, Up 32% QoQ
Psychedelics-focused mental health company Novamind Inc. (CSE:NM) (OTCQB: NVMDF) (FSE: HN2) reported its financial results for the three and six months ended December 31, 2021.
Benzinga’s Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022, in Miami, Florida.
Novamind Stock Dives On $3.95M Private Placement With Institutional Investor
Novamind Inc. (CSE: NM) (OTCQB: NVMDF) (FSE: HN2) announced Monday a CA$5 million ($3.95 million) private placement with an institutional investor.
Psychedelic Medicine: Major Health Providers Including Blue Cross Now Cover Ketamine Treatments
Four major health insurance providers recently approved psychedelic medicine company Novamind Inc. (CSE: NM) (OTCQB: NVMDF) for direct billing of intravenous (IV) ketamine for treatment-resistant depression (TRD).